IN THE CLAIMS:

1 – 89. (*Cancelled*)

90.(*Currently Amended*) A pharmaceutical dosage form for oral administration to a patient providing pulsed gastric release of methylphenidate comprising:

a) a gastric retention vehicle composition comprising ~~hydrogel, a~~ about 13 wt-% to about 30 wt-% superdisintegrant, ~~and~~ about 6 wt-% to about 12 wt-% tannic acid, and about 60 to about 85 wt-% of a hydrogel, whereby the gastric retention vehicle composition ~~providing~~ provides a homogenous solid matrix and the percentages are calculated with respect to the matrix exclusive of other excipients and the methylphenidate,

b) a plurality of first particles dispersed in the matrix, wherein the first particles contain methylphenidate, and

c) a plurality of second particles dispersed in the matrix, wherein the second particles contain methylphenidate, wherein each the second particles are coated with a coating that is impermeable to methylphenidate and dissolves in gastric fluid causing the coating to be breached by the gastric fluid,

wherein, upon contact with gastric fluid the gastric retention vehicle composition expands to promote retention of the dosage form in the patient's stomach and wherein methylphenidate is released from the first particles, and, after about 3 to 5 hours, the coating of the second particles is breached and methylphenidate is released from the second particles.

91.(*Original*) A pharmaceutical dosage form of claim 90 further comprising a plurality of third particles containing methylphenidate dispersed in the matrix, the third particles having a coating that is impermeable to the methylphenidate that dissolves in gastric fluid causing the coating to be breached by the gastric fluid, wherein, after about 3 to 5 hours after release of methylphenidate from the second particles, methylphenidate is released from the third particles.

92.(*Original*) A pharmaceutical dosage form of claim 90 wherein the first particles are coated with a coating that delays release of the methylphenidate from those particles.

93.(*Currently Amended*) A pharmaceutical dosage form for oral administration to a patient providing pulsed gastric release of methylphenidate comprising:

a) a gastric retention vehicle composition comprising about 60 wt-% to about 85 wt-% of a hydrogel, ~~a~~ about 13 wt-% to about 30 wt-% superdisintegrant and about 6 wt-% to about 12 wt-% tannic acid, the percentages calculated exclusive of other excipients or the methylphenidate,

b) a first reservoir containing methylphenidate, and

c) a second reservoir containing methylphenidate, wherein the second reservoir is coated with a coating that is impermeable to methylphenidate and dissolves in gastric fluid causing the coating to be breached by the gastric fluid,

wherein, upon contact with gastric fluid the gastric retention vehicle composition expands to promote retention of the dosage form in the patient's stomach and wherein methylphenidate is released from the first reservoir, and, after about 3 to 5 hours, the coating of the second reservoir is breached and methylphenidate is released from the second reservoir.

94.(*Original*) A pharmaceutical dosage form of claim 93 further comprising a third reservoir coated with a coating that is impermeable to methylphenidate and dissolves in gastric fluid causing the coating to be breached by the gastric fluid and methylphenidate to be released from the third reservoir about 3 to 5 hours after release of methylphenidate from the second reservoir.

95.(*Original*) A pharmaceutical dosage form of claim 93 wherein the first reservoir is coated with a coating that delays release of the methylphenidate from that reservoir.

96.(*Original*) A pharmaceutical dosage form of claim 93 wherein the gastric retention vehicle composition and the reservoirs are encapsulated.

97. – 112. (*Cancelled*)